期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study
1
作者 Yesim Gokce Kutsal Nurten Eskiyurt +39 位作者 Jale Irdesel Vesile Sepici Hatice Ugurlu Yesim Kirazli Fusun Ardic Mirko Korsic Tonko Vlak Mane Grlickov Snezana Markovic Temelkova Miroslav Lazarov Nada Pilipovic vera popovic Aleksandar Dimic Branka Kovacev Dorina Ruci Argjend Tafaj Elma Kucukalic-Selimovic Dijana Avdic Hajrija Seleskovic Snjezana Pejicic Bulent Butun Gulseren Akyuz Lale Cerrahoglu Omer Faruk Sendur Peyman Yalcin Sema Oncel Merih Saridogan Tunay Sarpel Mehmet Tosun Kazim Senel Savas Gursoy Ferhan Canturk Huseyin Demir Blazenka Miskic Dalibor Krpan Franjo Skreb Simeon Grazio Zeljka Crncevic-Orlic Fatih Ozdener Hakan Oncel 《Health》 2013年第7期30-40,共11页
A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once... A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a prospective, open-label, multicenter international study in patients with postmenopausal osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate for at least 3 months. Patients completed a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-QTM) at baseline for 6 months. Scores were converted to composite satisfaction scores (CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in the treatment phase and comprised the intent-to-treat (ITT) population, and 630 completed the study. In the ITT population, 68.1% patients answered “yes” to one or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of life and overall satisfaction domains (p scores for the side effects domains were significant (p < 0.001) in the CIQ “yes” group, but not for the degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change, p = 0.84) of non-gastrointestinal side effects. Of 638 patients who completed the preference questionnaire, 93.0% of patients preferred the once-monthly dosing schedule and 563 patients (90.7%) found it more convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%), and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference before switching treatment. 展开更多
关键词 BISPHOSPHONATE Compliance IBANDRONATE POSTMENOPAUSAL Osteoporosis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部